| 0.6301 -0.08 (-11.25%) | 08-12 12:20 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.81 |
1-year : | 0.87 |
| Resists | First : | 0.69 |
Second : | 0.74 |
| Pivot price | 0.67 |
|||
| Supports | First : | 0.61 |
Second : | 0.51 |
| MAs | MA(5) : | 0.7 |
MA(20) : | 0.67 |
| MA(100) : | 0.83 |
MA(250) : | 1.14 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 61.6 |
D(3) : | 77.1 |
| RSI | RSI(14): 40.9 |
|||
| 52-week | High : | 2.54 | Low : | 0.54 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HUMA ] has closed above bottom band by 25.9%. Bollinger Bands are 64.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.75 - 0.75 | 0.75 - 0.75 |
| Low: | 0.7 - 0.71 | 0.71 - 0.71 |
| Close: | 0.7 - 0.71 | 0.71 - 0.72 |
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Wed, 12 Aug 2026
Humacyte Q2 Earnings Call Highlights - Yahoo Finance
Wed, 12 Aug 2026
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Wed, 12 Aug 2026
Form 8K Humacyte Inc For: 12 August By Investing.com - Investing.com South Africa
Wed, 12 Aug 2026
Humacyte reports Q2 2026: Product revenue $0.4M, net loss $36.8M, cash $80.3M - TradingView
Tue, 11 Aug 2026
Humacyte Inc (HUMA) Q2 2026 Earnings Report Preview: What To Expect - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 270 (M) |
| Held by Insiders | 1.9613e+008 (%) |
| Held by Institutions | 7.5 (%) |
| Shares Short | 36,710 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0519e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 704 % |
| Return on Equity (ttm) | -51.5 % |
| Qtrly Rev. Growth | 2.02e+006 % |
| Gross Profit (p.s.) | -1.75 |
| Sales Per Share | -165.78 |
| EBITDA (p.s.) | -3.3085e+007 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -102 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 31.62 |
| Dividend | 0 |
| Forward Dividend | 3.228e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|